Home
›
Health
›
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
Health
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
The Guardian World
Tuesday 09 June 2026, 08:59 UTC
By Julia Kollewe
1 min read
Key Points
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...
British drugmaker’s new chief executive Luke Miels announces one of its biggest deals
GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications.
The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share in cash.
Continue reading...
Originally published by The Guardian World
Read original →